Comparative activity of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia

Journal of Antimicrobial Chemotherapy

Volumn 45, Issue 3, 2000, Pages 363-365

  Weiss, Karl ^a   Restieri, Christiane ^a   De Carolis, Emidio ^b   Laverdière, Michel ^a   Guay, Hélène ^a  

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CLINAFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLONE DERIVATIVE; SPARFLOXACIN; TROVAFLOXACIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; RESPIRATORY TRACT INFECTION; STENOTROPHOMONAS MALTOPHILIA;

EID: 0034049169     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/45.3.363     Document Type: Article

References (10)

1. Denton, M. & Kerr, K. G. (1998). Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clinical Microbiology Reviews 11, 57-80.
2. Vartivarian, S., Anaissie, E., Bodey, G., Sprigg, H. & Rolston, K. (1994). A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy. Antimicrobial Agents and Chemotherapy 38, 624-7.
3. National Committee for Clinical Laboratory Standards. (1997). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Fourth Edition: Approved Standard M7-A4. NCCLS, Villanova, PA.
4. Pankuch, G. A., Jacobs, M. R. & Applebaum, P. C. (1994). Susceptibilities of 123 Xanthomonas maltophilia to clinafloxacin, PD 131628, PD 138312, PD 140248, ciprofloxacin and ofloxacin. Antimicrobial Agents and Chemotherapy 38, 369-70.
5. Ford, A. S., Baltch, A. L., Smith, R. P. & Ritz, W. (1993). In-vitro susceptibilities of Pseudomonas aeruginosa and Pseudomonas spp. to the new fluoroquinolones clinafloxacin and PD 131628 and nine other antimicrobial agents. Journal of Antimicrobial Chemotherapy 31, 523-32.
6. Rolston, K. V., Messer, M. & Ho, D. H. (1990). Comparative in vitro activities of newer quinolones against Pseudomonas species and Xanthomonas maltophilia isolated from patients with cancer. Antimicrobial Agents and Chemotherapy 34, 1812-3.
7. Visalli, M. A., Jacobs, M. R. & Appelbaum, P. C. (1998). Activities of three quinolones, alone, and in combination with extended-spectrum cephalosporins or gentamicin, against Stenotrophomonas maltophilia. Antimicrobial Agents and Chemotherapy 42, 2002-5.
8. Zhanel, G., Walkty, A., Vercaigne, L., Karlowsky, J. A., Embil, J., Gin, A. et al. (1999). The new fluoroquinolones: a critical review. Canadian Journal of Infectious Diseases 10, 207-38.
9. Lecso-Bornet, M., Pierre, J., Sarkis-Karam, D., Lubera, S. & Bergogne-Berezin, E. (1992). Susceptibility of Xanthomonas maltophilia to six quinolones and study of outer membrane proteins in resistant mutants selected in vitro. Antimicrobial Agents and Chemotherapy 36, 669-71.
10. Muder, R. R., Harris, A. P., Muller, S., Edmond, M., Chow, J. W., Papadakis, K. et al. (1996). Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective multicenter study of 91 episodes. Clinical Infectious Diseases 22, 508-12. Received 8 September 1999; returned 27 October 1999; revised 11 November 1999; accepted 22 November 1999